| Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same -> Monitor Keywords |
|
|
  Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the sameUSPTO Application #: 20070106064Title: Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same Abstract: A solid phase synthesis method for preparing peptide-spacer-lipid conjugates, the peptide-spacer-lipid conjugates synthesized by the method, and liposomes containing the peptide-spacer-lipid conjugates. The present invention provides a convenient solid phase synthesis method for preparing peptide-spacer-lipid conjugates and provides various linkage groups (such as amide group) for conjugating peptide, spacer and lipid, wherein the spacer may comprise PEG. Several advantages can be achieved, such as the synthetic procedure can be simplified, the synthesis process can be set to automation, the purification is easier in each reaction step, and the product losses can be reduced to minimal during synthesis. The present synthesis method is suitable for preparing a wide range of peptide-spacer-lipid conjugates, provides a peptide-spacer-lipid conjugate prepared by the solid phase synthesis method of the present invention, which can be incorporated into a liposome as the targeting moiety for liposomal drug delivery to specific cells, and provides a targeting liposome containing the present peptide-spacer-lipid conjugate. (end of abstract) Agent: Ladas & Parry - New York, NY, US Inventors: Shih-Kwang Wu, Ting-Gung Chang, Ghin-Lu Tseng, Li-Jung Chen, Kae-Shyang Shih USPTO Applicaton #: 20070106064 - Class: 530317000 (USPTO) Related Patent Categories: Chemistry: Natural Resins Or Derivatives; Peptides Or Proteins; Lignins Or Reaction Products Thereof, Peptides Of 3 To 100 Amino Acid Residues, Cyclic Peptides The Patent Description & Claims data below is from USPTO Patent Application 20070106064. Brief Patent Description - Full Patent Description - Patent Application Claims
[0001] This application is a divisional of application Ser. No. 10/308,644 filed Dec. 3, 2002, which is a continuation-in-part of application Ser. No. 10/016,569 filed Dec. 7, 2001 claims the benefit thereof and incorporates the same by reference. FIELD OF THE INVENTION [0002] The present invention is related to solid phase synthesis method for preparing peptide-spacer-lipid conjugates and uses of the conjugates. BACKGROUND OF THE INVENTION [0003] Drug delivery plays a crucial role in the improvement of agents for therapeutic treatment, since many agents have unfavorable drawbacks if they are directly applied to a human body. Therefore, developing a delivery system is necessary for a particular agent to improve its availability such as reduction of side effects, enhancement of efficacy, and convenience in usage. For example, antineoplastic chemotherapies are limited by adverse side effects resulting from their widespread toxicity to normal tissues. Therefore, a delivery system which could prevent drug diffusion and concentrate the drug to the disease site is required. [0004] Liposomes can provide several advantages for use as a drug delivery system for the reasons that they are safe to a biological system, have an excellent spherical bilayer for carrying ether hydrophilic or hydrophobic drugs, and can prevent drugs from degradation and diffusion. Moreover, liposomes can be modified to have additional functions for specific purposes. A successful example is shown as polyethylene-glycerol-grafted (PEG-grafted) liposomes. These modified liposomes can evade the reticuloendothelial system and have prolonged circulation time in blood. Furthermore, cytotoxic cancer drugs encapsulated in the PEG-grafted liposomes provide a remarkable enhancement in anti-tumor activity effect and decrease the side effect of the toxicity to the normal cells. The PEG-grafted liposomes thereby gained commercial application and opened the possibility for further modification of these PEG-grafted liposomes for targeted delivery. [0005] Several types of targeted liposomes have been developed (Maruyama et al., Biochim Biophys Acta. 1995, 1234, 74-80; and Allen T M, Trends Pharmacol Sci. 1994, 15, 215-220). Commonly used targeted liposomes include (1) targeting ligands linked at the lipid headgroups on the conventional liposomes (Type A); (2) targeting ligands linked at the lipid headgroups on the PEG-grafted liposomes (Type B); and (3) targeting ligands attached at the distal end of the PEG chain on the PEG-grafted liposomes (Type C). To date, studies have shown that targeted liposomes of Type C provide a better liposomal structure for targeted delivery (Maruyama et al., Biochim Biophys Acta. 1995, 1234, 74-80). Based on this liposomal structure, several types of, molecules, such as antibodies (Ahmad et al., Cancer Res. 1993, 53, 1484-8; and Suzuki et al., Biochim Biophys Acta., 1995, 1245, 9-16), proteins (Eavarone et al., J Biomed Mater Res. 2000, 51, 10-4) small synthesis molecules (Gabizon et al., Bioconjug Chem. 1999, 10, 289-98) and peptides (Zalipsky et al., Bioconjug Chem. 1997, 8, 11-1-8), have been developed as the targeting ligands for binding the target sites. Among these types of molecules, peptides are considered as highly potential targeting ligands, since a peptide can serve as a recognition component in protein-protein interactions such as receptor-ligand interactions. Furthermore, many cellular membrane receptors associated with diseases have been studied. [0006] Peptides, such as RGD-peptides, somatostatin, chemotactic peptides, vasoactive intestinal peptide, and mimetics thereof, are good candidates as the targeting ligands. Many counter receptors of these peptides have been found being overexpressed in various tumor cells. Moreover, peptides and peptide mimetics have several unique advantages over other type of molecules (e.g. antibodies). Generally, these peptides bind to target cells with a ligand-receptor association at high affinity and enter the intercellular compartments through receptor-mediate endocytosis. However, an antibody-based targeted liposome may not utilize the endocytosis pathway into the interior of the cells by the antigen on the cell membrane. Furthermore, peptides have less opportunity to be recognized by the reticuloendothelial system and are, thus, cleared from the blood circulation system. Peptide mimetics can provide a higher binding affinity and a better resistance to the proteases degradation than nature peptides. [0007] Currently, two approaches for preparing peptide-based targeted liposomes have been developed, whereby the peptide ligands can be attached at the distal end of PEGs. The first approach is incorporating end-group functionalized PEG-lipid conjugates into liposomes and then conjugating with peptide ligands (Zalipsky et al., Bioconjug. Chem., 1995, 6, 705-8). However, when the end-group functionalized PEGs are conjugated to peptide ligands, a non-homogeneous conjugation may happen if there is more than one reaction group in the peptide ligands. Furthermore, the unreacted end-groups of functionalized PEG are difficult to define and are completely deactivate after the coupling reaction. The second approach is directly incorporating the peptide-PEG-lipid conjugates into liposomal membranes (Zalipsky et al., Bioconjug. Chem., 1997 8, 111-8). This approach can provide a structurally well-defined targeted liposome component. [0008] Although peptide-PEG-lipid conjugates are the expected molecules for preparing the targeted liposomes, the available conjugates are still very limited and the synthesis is difficult. This is so, because, in the peptide-PEG-lipid conjugates, the chemical property of the side chains in peptides is diverse, the molecular mass of PEG is heterogeneous, and the nature of lipids is amphiphilic. These properties cause difficulty in the synthetic processes of side chain protection, purification, and reaction and is evident in that very few peptide-PEG-lipid conjugates have been synthesized and in that the conjugation of a peptide, a spacer, and a lipid often induce the formation of a clumsy linker and an unusual functional group. [0009] Zalipsky et al. (1997) discloses the method for synthesizing YIGSR-PEG-lipid conjugates. However, this method cannot be used as a general method for synthesizing a broad range of peptide-PEG-lipid conjugates as a nonspecific reaction of bromoacetyl group with strong nucleophilic residues, such as an amino group or other thiol group, in the peptide may occur. Furthermore, in the YIGSR-PEG-lipid conjugate, a thioacetyl (--S--CH2-CO--) linker was used for conjugating the peptide and PEG, which is unfavorable in industrialization since an additional modification at the ends of peptide and PEG to a bromoacetyl group and a thiol group, respectively, is required. The urethane linkage between PEG and lipid in the YIGSR-PEG-lipid conjugate is unnatural and acid-base labile. Therefore, a need exists for a synthesis method of preparing a broad range of peptide-spacer-lipid conjugates. [0010] Even though EP 1 118 336 illustrates the synthesis of the Octreotide-spacer-PEG-spacer-DOPE conjugate, the coupling of Octreotide and DOPE by a spacer-PEG-spacer involves four functional groups and three pieces of spacer, which will cause the molecules more complicated and unfavorable for molecule characterization and industrial usages. BRIEF SUMMARY OF THE INVENTION [0011] The present invention provides a convenient solid phase synthesis method for preparing peptide-PEG-lipid conjugates and provides various linkage groups (such as amide group) for conjugating a peptide, a spacer and a lipid. According to the solid phase synthesis method of the present invention, several advantages can be achieved, such as the simplified synthetic, an automated synthesis, a facile purification process in each reaction step, and minimized product losses during synthesis. In addition, the present synthesis method is suitable for preparing a wide range of peptide-spacer-lipid conjugates. [0012] The present invention also provides a peptide-spacer-lipid conjugate, prepared by the present solid phase synthesis method. The peptide-spacer-lipid can be incorporated into a liposome as the targeting moiety for liposomal drug delivery to specific cells. [0013] The present invention also provides a targeting liposome comprising the present peptide-spacer-lipid conjugate. ABBREVIATION LIST [0014] The present invention is herein disclosed using the following chemical nomenclature: [0015] 2-Br-Cbz 2-bromobenzyloxycarboyl [0016] 2-Br-Z 2-bromobenzyloxycarbonyl [0017] 2-Cl-Cbz 2-chlorobenzyloxycarboyl [0018] 2-Cl-Z 2-chlorobenzyloxycarbonyl [0019] Abu 4-aminobutyric acid [0020] AC acetyl [0021] Acm acetamidomethyl [0022] Boc t-butyloxycarbonyl [0023] Bz benzoyl [0024] Bzl benzyl [0025] Cbz benzyloxycarboyl [0026] DCC dicyclohexylcarbodiimide [0027] DC-Chol 3.beta.[N--(N',N'-dimethylaminoethane)carbamyl]cholesterol [0028] DCM Dichloromethane [0029] DDAB dimethylammonium bromide [0030] Dde 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl [0031] DIPCDI 1,3-diisopropylcarbodiimide [0032] DMAP dimethylaminopyridine [0033] DME ethylene glycol dimethyl ether [0034] DMF N,N-dimethylformamide [0035] DMRIE N-[1-(2,3-ditetradecyloxy)propyl]-N,N-dimethyl-N-hydroxyethylammonium bromide [0036] DMS dimethylsulfide [0037] DOPAT 1,2-dioleyloxy-3-(trimethylamino) propane [0038] DOPE dioleoyl phosphatidylethanolamine [0039] DORIE N-[1-(2,3-dioleoyloxy)propyl]-N,N-dimethyl-N-hydroxy ethylammonium bromide [0040] DOTMA N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium cholide [0041] DOX doxorubicin [0042] DSPE distearyl phosphatidylethanolamine [0043] EDC 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide [0044] EDT ethanedithiol [0045] EGF epidermal growth factor [0046] FGF fibroblast growth factor [0047] Fmoc 9-fluorenylmethyloxycarbonyl [0048] For formyl [0049] HF hydrogen fluoride [0050] HGF hepatocyte growth factor [0051] HOBt N-hydroxybenzotriazole [0052] HSPC hydrogenated soybean phosphatidylcholine [0053] IGF insulin-like growth factor [0054] Im imidazol-1-yl [0055] MBHA 4-methylbenzhydrylamide [0056] MeOH methanol [0057] Mmt 4-methoxytrityl [0058] Mtr 4-methoxy-2,3,6-trimethylbenzene-sulfonyl [0059] Mts mesitylene-2-sulfonyl [0060] Mtt 4-methlytrityl [0061] mPEG-DSPE methoxypolyethylene glycol-distearyl phosphatidylethanol amine [0062] NGF nerve growth factor [0063] NHS N-hydroxysuccinimide [0064] PACAP pituitary adenylate cyclase-activating peptide [0065] Pbf 2,2,4,6,7-pentamethyldihydro-benzofuran-5-sulfonyl [0066] PDGF platelet-derived growth factor [0067] Pd--C Palladium supported on active carbon catalysts [0068] PEG polyethylene glycol [0069] pMeoBzl p-methoxybenzyl [0070] Pmc 2,2,5,7,8-pentamethylchroman-6-sulfonyl [0071] pNP para-nitrophenyl [0072] SPPS solid phase peptide synthesis [0073] SST somatostatin [0074] Su succinimide [0075] TCP 2,4,5-trichlorophenyl [0076] TEA triethylamine [0077] TFA trifluoroacetic acid [0078] TFE trifluoroethanol [0079] TFMSA trifluoromethanesulfonic acid [0080] Tf trifluoromethanesulfonyl [0081] Tfa trifluoroacetyl [0082] TGF transforming growth factor [0083] THP tetrahydropyranyl [0084] Tos tosyl [0085] Trt trityl [0086] tBu tert-butyl [0087] tbuthio tert-butylthio [0088] VEGF vascular endothelial growth factor [0089] VIP vasoactive intestinal peptide [0090] Z benzyloxycarbonyl DETAILED DESCRIPTION OF THE INVENTION [0090] I. Solid Phase Synthesis Method for Preparing Peptide-Spacer-Lipid Conjugates [0091] According to the present invention, a solid phase synthesis method for preparing a peptide PEG-phospholipid conjugate, which comprises the steps of: (1) synthesizing an amino acid residue protected peptidyl resin in solid phase; (2) conjugating a PEG and a phospholipid to the peptidyl resin to form a peptide PEG-phospholipid resin; (3) cleaving the peptide PEG-phospholipid resin to obtain a peptide-PEG-phospholipid; Continue reading... Full patent description for Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same or other areas of interest. ### Previous Patent Application: Method for extracting insulins by improved air-gassing of a folding Next Patent Application: Tat- 001 and methods of assessing and treating cancer Industry Class: Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof ### FreshPatents.com Support Thank you for viewing the Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same patent info. IP-related news and info Results in 0.20624 seconds Other interesting Feshpatents.com categories: Electronics: Semiconductor , Audio , Illumination , Connectors , Crypto , |
||
